These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30775501)

  • 1. Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study.
    Tanaka M; Nakamura Y; Itoh S; Kato Y
    Osteoporos Sarcopenia; 2017 Mar; 3(1):37-44. PubMed ID: 30775501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study.
    Suzuki T; Nakamura Y; Kato H
    Osteoporos Sarcopenia; 2019 Dec; 5(4):122-127. PubMed ID: 31938731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
    Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients.
    Mukaiyama K; Uchiyama S; Nakamura Y; Ikegami S; Taguchi A; Kamimura M; Kato H
    Tohoku J Exp Med; 2015 Dec; 237(4):339-43. PubMed ID: 26639092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation.
    Tanaka M; Itoh S; Takeuchi Y
    Osteoporos Sarcopenia; 2018 Sep; 4(3):102-108. PubMed ID: 30775551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
    Nakatoh S
    J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis.
    Uehara M; Nakamura Y; Suzuki T; Nakano M; Takahashi J
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis.
    Nakamura Y; Suzuki T; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Tohoku J Exp Med; 2017 Apr; 241(4):319-326. PubMed ID: 28458336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis.
    Takada J; Ikeda S; Kusanagi T; Mizuno S; Wada H; Iba K; Yoshizaki T; Yamashita T
    Clin Cases Miner Bone Metab; 2016; 13(1):25-8. PubMed ID: 27252739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis.
    Kamimura M; Ikegami S; Mukaiyama K; Koiwai H; Nakamura Y; Taguchi A; Kato H
    Osteoporos Sarcopenia; 2019 Jun; 5(2):57-61. PubMed ID: 31346557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
    J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats.
    Sakai S; Takeda S; Sugimoto M; Shimizu M; Shimonaka Y; Yogo K; Hashimoto J; Bauss F; Endo K
    Bone; 2015 Dec; 81():449-458. PubMed ID: 26281770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
    Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats.
    Yano T; Ito T; Kanehira Y; Yamada M; Kimura-Suda H; Wagatsuma H; Inoue D
    Bone Rep; 2021 Jun; 14():101061. PubMed ID: 33898659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment.
    Nakamura Y; Suzuki T; Kato H
    Ther Clin Risk Manag; 2017; 13():1343-1348. PubMed ID: 29062234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis.
    Ono Y; Miyakoshi N; Kasukawa Y; Nagasawa H; Tsuchie H; Akagawa M; Nagahata I; Yuasa Y; Sato C; Shimada Y
    Osteoporos Sarcopenia; 2018 Dec; 4(4):128-133. PubMed ID: 30775555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRACP-5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia.
    Ota I; Ota Y; Ota K; Eda H; Ohta H
    JBMR Plus; 2022 Nov; 6(11):e10690. PubMed ID: 36398113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of eldecalcitol, a new active vitamin D3 analog, in the bone metabolism of postmenopausal women receiving maintenance hemodialysis.
    Sasaki N; Tsunoda M; Ikee R; Hashimoto N
    J Bone Miner Metab; 2015 Mar; 33(2):213-20. PubMed ID: 24763728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis.
    Cui L; Xia W; Yu C; Dong S; Pei Y
    Arch Osteoporos; 2022 May; 17(1):74. PubMed ID: 35513519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.
    Hagino H; Sakai A; Ikeda S; Imanishi Y; Tsurukami H; Nakajo S; Miyakoshi N
    J Bone Miner Metab; 2019 Nov; 37(6):1013-1023. PubMed ID: 31098670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.